RAF and MEK inhibitors are effective in BRAF-mutant melanoma but not in BRAF-mutant
colorectal cancer. To gain additional insights into this difference, we performed a genome …

BRAF mutations occur in approximately 10% of colorectal cancers. Although RAF inhibitor
monotherapy is highly effective in BRAF-mutant melanoma, response rates in BRAF-mutant …

Activating mutations in the KRAS and BRAF genes, leading to hyperactivation of the
RAS/RAF/MAPK oncogenic signaling cascade, are common in patients with colorectal …

BRAF mutations occur in 10% to 15% of colorectal cancers and confer adverse outcome in
the metastatic setting. Although RAF inhibitors such as vemurafenib (PLX4032) have proven …

Abstract BRAF V600E colorectal cancers are insensitive to RAF inhibitor monotherapy due
to feedback reactivation of receptor tyrosine kinase signaling. Combined RAF and EGFR …

Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved
efficacy in BRAF-mutant colorectal cancer, emergence of acquired resistance limits clinical …

RAF kinase is crucially involved in cell proliferation and survival in colorectal cancer (CRC).
Patients with metastatic CRC (mCRC) harboring BRAF mutations (BRAFms) not only …

Background Mounting evidence suggests that RAF-mediated MEK activation plays a crucial
role in paradox MAPK (re) activation, leading to resistance and therapeutic failure with …

Oncogenic BRAF mutations are found in several tumor types, including melanomas and
colorectal cancers. Tumors with BRAF mutations have increased mitogen-activated protein …

RAF, a core signaling component of the MAPK kinase cascade, is often mutated in various
cancers, including melanoma, lung, and colorectal cancers. The approved inhibitors were …